Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinología ginecológica de clínica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinología ginecológica

M. Parra; N. Lagos; M. Levancini; M. Villarroel; E. Pizarro; P. Vanhauwaert; S. Velasco; M. Fernadez; M. Gambacciani; N. Biglia; A. Cagnacci; S. Caruso; E. Cicinelli; V. De Leo; C. Di Carlo; M. Farris; A. Gambera; S. Guaschino; A. Lanzone; A. M. Paoletti; N. Russo; F. Vicariotto; P. Villa; A. Volpe; P. Lavin; M. Lopez; C. Campusano; P. Barriga; S. Brantes

doi:10.4067/s0717-75262018000500527

Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinología ginecológica de clínica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinología ginecológica

Translated title of the contribution: 2018 recommendations on menopause and menopausal hormone therapy of the Gynecological Endocrinology Unit of the German Clinic of Santiago-Italian Society of Menopause and the Chilean Society of Gynecological Endocrinology

M. Parra, N. Lagos, M. Levancini, M. Villarroel, E. Pizarro, P. Vanhauwaert, S. Velasco, M. Fernadez, M. Gambacciani, N. Biglia, A. Cagnacci, S. Caruso, E. Cicinelli, V. De Leo, C. Di Carlo, M. Farris, A. Gambera, S. Guaschino, A. Lanzone, A. M. PaolettiN. Russo, F. Vicariotto, P. Villa, A. Volpe, P. Lavin, M. Lopez, C. Campusano, P. Barriga, S. Brantes

Clínica Universidad de los Andes

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

In the last decade, the risk benefits ratio of MHT has been evaluated mainly in terms of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these Recommendations is to provide a simple and updated reference on postmenopausal MHT. The term MHT typically includes estrogen replacement therapy (ERT) and estrogen-progestogen therapy (EPT). EPT can be sequential (Seq) when progestogen is added to ERT for 10-14 days a month, or continuous combined (CC) when progestogen is administered continuously every day along with a fixed amount of estrogen. MHT also includes Tibolone and the Tissue Selective Estrogen Complex (TSEC).

Translated title of the contribution	2018 recommendations on menopause and menopausal hormone therapy of the Gynecological Endocrinology Unit of the German Clinic of Santiago-Italian Society of Menopause and the Chilean Society of Gynecological Endocrinology
Original language	Spanish
Pages (from-to)	527-550
Number of pages	24
Journal	Revista Chilena de Obstetricia y Ginecologia
Volume	83
Issue number	5
DOIs	https://doi.org/10.4067/s0717-75262018000500527
State	Published - Nov 2018

Bibliographical note

Publisher Copyright:
© 2018 Sociedad Chilena de Obstetricia y Ginecologia. All rights reserved.

Access to Document

10.4067/s0717-75262018000500527

Fingerprint

Dive into the research topics of '2018 recommendations on menopause and menopausal hormone therapy of the Gynecological Endocrinology Unit of the German Clinic of Santiago-Italian Society of Menopause and the Chilean Society of Gynecological Endocrinology'. Together they form a unique fingerprint.

Cite this

Parra, M., Lagos, N., Levancini, M., Villarroel, M., Pizarro, E., Vanhauwaert, P., Velasco, S., Fernadez, M., Gambacciani, M., Biglia, N., Cagnacci, A., Caruso, S., Cicinelli, E., De Leo, V., Di Carlo, C., Farris, M., Gambera, A., Guaschino, S., Lanzone, A., ... Brantes, S. (2018). Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinología ginecológica de clínica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinología ginecológica. Revista Chilena de Obstetricia y Ginecologia, 83(5), 527-550. https://doi.org/10.4067/s0717-75262018000500527

Parra, M. ; Lagos, N. ; Levancini, M. et al. / Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinología ginecológica de clínica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinología ginecológica. In: Revista Chilena de Obstetricia y Ginecologia. 2018 ; Vol. 83, No. 5. pp. 527-550.

@article{e86f708a37ea436a86ede28c439cbcff,

title = "Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinolog{\'i}a ginecol{\'o}gica de cl{\'i}nica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinolog{\'i}a ginecol{\'o}gica",

abstract = "In the last decade, the risk benefits ratio of MHT has been evaluated mainly in terms of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these Recommendations is to provide a simple and updated reference on postmenopausal MHT. The term MHT typically includes estrogen replacement therapy (ERT) and estrogen-progestogen therapy (EPT). EPT can be sequential (Seq) when progestogen is added to ERT for 10-14 days a month, or continuous combined (CC) when progestogen is administered continuously every day along with a fixed amount of estrogen. MHT also includes Tibolone and the Tissue Selective Estrogen Complex (TSEC).",

author = "M. Parra and N. Lagos and M. Levancini and M. Villarroel and E. Pizarro and P. Vanhauwaert and S. Velasco and M. Fernadez and M. Gambacciani and N. Biglia and A. Cagnacci and S. Caruso and E. Cicinelli and {De Leo}, V. and {Di Carlo}, C. and M. Farris and A. Gambera and S. Guaschino and A. Lanzone and Paoletti, {A. M.} and N. Russo and F. Vicariotto and P. Villa and A. Volpe and P. Lavin and M. Lopez and C. Campusano and P. Barriga and S. Brantes",

year = "2018",

month = nov,

doi = "10.4067/s0717-75262018000500527",

language = "Spanish",

volume = "83",

pages = "527--550",

journal = "Revista Chilena de Obstetricia y Ginecologia",

issn = "0048-766X",

publisher = "Sociedad Chilena de Obstetricia y Ginecologia",

number = "5",

}

Parra, M, Lagos, N, Levancini, M, Villarroel, M, Pizarro, E, Vanhauwaert, P, Velasco, S, Fernadez, M, Gambacciani, M, Biglia, N, Cagnacci, A, Caruso, S, Cicinelli, E, De Leo, V, Di Carlo, C, Farris, M, Gambera, A, Guaschino, S, Lanzone, A, Paoletti, AM, Russo, N, Vicariotto, F, Villa, P, Volpe, A, Lavin, P, Lopez, M, Campusano, C, Barriga, P & Brantes, S 2018, 'Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinología ginecológica de clínica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinología ginecológica', Revista Chilena de Obstetricia y Ginecologia, vol. 83, no. 5, pp. 527-550. https://doi.org/10.4067/s0717-75262018000500527

Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinología ginecológica de clínica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinología ginecológica. / Parra, M.; Lagos, N.; Levancini, M. et al.
In: Revista Chilena de Obstetricia y Ginecologia, Vol. 83, No. 5, 11.2018, p. 527-550.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinología ginecológica de clínica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinología ginecológica

AU - Parra, M.

AU - Lagos, N.

AU - Levancini, M.

AU - Villarroel, M.

AU - Pizarro, E.

AU - Vanhauwaert, P.

AU - Velasco, S.

AU - Fernadez, M.

AU - Gambacciani, M.

AU - Biglia, N.

AU - Cagnacci, A.

AU - Caruso, S.

AU - Cicinelli, E.

AU - De Leo, V.

AU - Di Carlo, C.

AU - Farris, M.

AU - Gambera, A.

AU - Guaschino, S.

AU - Lanzone, A.

AU - Paoletti, A. M.

AU - Russo, N.

AU - Vicariotto, F.

AU - Villa, P.

AU - Volpe, A.

AU - Lavin, P.

AU - Lopez, M.

AU - Campusano, C.

AU - Barriga, P.

AU - Brantes, S.

PY - 2018/11

Y1 - 2018/11

N2 - In the last decade, the risk benefits ratio of MHT has been evaluated mainly in terms of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these Recommendations is to provide a simple and updated reference on postmenopausal MHT. The term MHT typically includes estrogen replacement therapy (ERT) and estrogen-progestogen therapy (EPT). EPT can be sequential (Seq) when progestogen is added to ERT for 10-14 days a month, or continuous combined (CC) when progestogen is administered continuously every day along with a fixed amount of estrogen. MHT also includes Tibolone and the Tissue Selective Estrogen Complex (TSEC).

AB - In the last decade, the risk benefits ratio of MHT has been evaluated mainly in terms of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these Recommendations is to provide a simple and updated reference on postmenopausal MHT. The term MHT typically includes estrogen replacement therapy (ERT) and estrogen-progestogen therapy (EPT). EPT can be sequential (Seq) when progestogen is added to ERT for 10-14 days a month, or continuous combined (CC) when progestogen is administered continuously every day along with a fixed amount of estrogen. MHT also includes Tibolone and the Tissue Selective Estrogen Complex (TSEC).

UR - http://www.scopus.com/inward/record.url?scp=85057760515&partnerID=8YFLogxK

U2 - 10.4067/s0717-75262018000500527

DO - 10.4067/s0717-75262018000500527

M3 - Article

AN - SCOPUS:85057760515

SN - 0048-766X

VL - 83

SP - 527

EP - 550

JO - Revista Chilena de Obstetricia y Ginecologia

JF - Revista Chilena de Obstetricia y Ginecologia

IS - 5

ER -

Parra M, Lagos N, Levancini M, Villarroel M, Pizarro E, Vanhauwaert P et al. Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinología ginecológica de clínica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinología ginecológica. Revista Chilena de Obstetricia y Ginecologia. 2018 Nov;83(5):527-550. doi: 10.4067/s0717-75262018000500527

Menopausia y terapia hormonal de la menopausia las recomendaciones 2018 de la unidad de endocrinología ginecológica de clínica alemana de santiago-Sociedad Italiana de la menopausia y la sociedad Chilena de endocrinología ginecológica

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this